No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 308 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... June 2, 2020 Sustainability a major focus of our 17th year partnering with TK... October 11, 2021 When You and Your Child Have VHL: 8 Ways to Cope August 11, 2020 Why the Fear of Cancer Recurrence Is Often Misunderstood and How... December 6, 2022 Load more HOT NEWS Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery Firefighters Band Together To Raise $30k For Breast Cancer Research &... Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... Peace
